AstraZeneca, the U.K.-Swedish pharmaceutical giant, on Tuesday announced a plan to invest some $50 billion in the U.S. in a move hailed by the Trump administration — though much of what it is announcing it’s already announced before.

U.K.-based drug giant AstraZeneca will make what it calls its single-largest manufacturing investment in the world with a new facility in Virginia.

President Donald Trump referenced the announcement the following day in Oval Office remarks, framing AstraZeneca’s overall $50 billion investment as a response to U.S. trade policy and the political climate.